Healthcare
Rani Therapeutics Holdings, Inc.(RANI)
Live Price
Offline$0.782
+2.22% today
1Y Change
+56.16%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $60.00M
- Revenue Growth
- +58.9%
- EPS Growth
- +57.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rani Therapeutics Holdings, Inc. (RANI) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $0.78 and up 56.2% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +58.9%, EPS growth of +57.1%, a dividend yield of 0.0%. What stands out right now is revenue +58.9%, EPS +57.1%, free cash flow +47.4% with operating margin -2345.9% and ROIC -80.6%. Valuation already assumes a fairly strong business story at price/sales 37.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RANI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+58.9% vs +7.6% peer median
Operating Margin
Below sector median
-2345.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +58.9% and EPS at +57.1%, with operating margin around -2345.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -18.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -4.5% | -19.6% | -28.8% |
2026 Mar 26, 2026 | -133.3% | -24.9% | -22.2% | -13.1% |
2025 Nov 6, 2025 | -33.3% | -11.0% | -15.0% | -30.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RANI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RANI Max Drawdown
-74.21%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RANI and SPY.
Company Overview
Rani Therapeutics Holdings, Inc.
NASDAQ Global Market
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
- Leadership
- Talat Imran
- IPO Date
- Jul 30, 2021
- Employees
- 105
- Street Address
- 2051 Ringwood Avenue
- Mailing
- San Jose, CA, 95131
- Region
- San Jose, CA, US
- Reporting Currency
- USD
- Investor Line
- 408 457 3700
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 37.6
- Price/Book
- 4.2
Growth
- Revenue
- +58.9%
- EPS
- +57.1%
- Free Cash Flow
- +47.4%
Profitability
- Gross Margin
- 75.0%
- Operating Margin
- -2345.9%
- Net Margin
- -1817.1%
- ROE
- -718.5%
- ROIC
- -80.6%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 4.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.